首页> 美国卫生研究院文献>International Journal of Nanomedicine >Nano-hole induction by nanodiamond and nanoplatinum liquid DPV576 reverses multidrug resistance in human myeloid leukemia (HL60/AR)
【2h】

Nano-hole induction by nanodiamond and nanoplatinum liquid DPV576 reverses multidrug resistance in human myeloid leukemia (HL60/AR)

机译:纳米金刚石和纳米铂液体DPV576诱导的纳米孔逆转了人类髓样白血病(HL60 / AR)的多药耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently nanoparticles have been extensively studied and have proven to be a promising candidate for cancer treatment and diagnosis. In the current study, we examined the chemo-sensitizing activity of a mixture of nanodiamond (ND) and nanoplatinum (NP) solution known as DPV576, against multidrug-resistant (MDR) human myeloid leukemia (HL60/AR) and MDR-sensitive cells (HL60). Cancer cells were cultured with different concentrations of daunorubicin (DNR) (1 × 10 −9−1 × 10 −6 M) in the presence of selected concentrations of DPV576 (2.5%–10% v/v). Cancer cell survival was determined by MTT assay, drug accumulation by flow cytometry and confocal laser scanning microscopy (CLSM), and holes and structural changes by atomic force microscopy (AFM). Co-treatment of HL60/AR cells with DNR plus DPV576 resulted in the reduction of the IC50 to 1/4th. This was associated with increased incidences of holes inside the cells as compared with control untreated cells. On the other hand, HL60 cells did not show changes in their drug accumulation post-treatment with DPV576 and DNR. We conclude that DPV576 is an effective chemo-sensitizer as indicated by the reversal of HL60/AR cells to DNR and may represent a potential novel adjuvant for the treatment of chemo-resistant human myeloid leukemia.
机译:最近,对纳米粒子进行了广泛的研究,并被证明是用于癌症治疗和诊断的有希望的候选者。在当前的研究中,我们检查了称为DPV576的纳米金刚石(ND)和纳米铂(NP)溶液的混合物对耐多药(MDR)的人类髓样白血病(HL60 / AR)和MDR敏感细胞的化学增敏活性(HL60)。在选定浓度的DPV576(2.5)下,将癌细胞与不同浓度的柔红霉素(DNR)(1×10 −9 -1×10 -6 M)一起培养%–10%v / v)。通过MTT分析,通过流式细胞术和共聚焦激光扫描显微镜(CLSM)进行的药物积累以及通过原子力显微镜(AFM)进行的孔和结构变化来确定癌细胞的存活率。 HL60 / AR细胞与DNR加DPV576的共处理导致IC50降低至1/4。与未处理的对照细胞相比,这与细胞内孔的发生率增加有关。另一方面,用DPV576和DNR处理后,HL60细胞的药物蓄积没有变化。我们得出的结论是,如HL60 / AR细胞逆转为DNR所示,DPV576是一种有效的化学增敏剂,可能代表了潜在的新型佐剂,可用于治疗抗化学性的人类骨髓性白血病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号